PureCycle Technologies (PCT) Stock Forecast & Price Target

PureCycle Technologies is viewed positively because its patented, exclusive P&G-originated dissolution technology and first-mover position support a differentiated route to near-virgin polypropylene, while recent operating setbacks at Ironton were described as resolved. Customer validation is strengthening, with 72 active trials, 20 qualified applications, 61 samples shipped, 67 programs advancing a qualification stage, and completed qualification of recycled caps for a L’Oréal application, alongside P&G products now on shelves. Although production estimates were trimmed to stay conservative, the company still had about $393M of liquidity in Q3 and is advancing a 130M-pound Thailand facility, Antwerp permits for 1H27, and long-term scale opportunities through Gen-2 and Japan.

PureCycle Technologies is viewed negatively because its commercial ramp is still lagging badly, with 3Q26 revenue of about $2.3M falling well short of estimates and even declining from 2Q26. Although New Jersey extended the food-contact PCR exemption through 2030 and could support roughly 50M lbs/year of expected volume across 15 programs, that demand is now spread over the next three years rather than arriving by 4Q26, delaying monetization. The company also remains financially strained, posting a 3Q26 net loss of about $6.9M and seeing cash fall to roughly $109M from $165M in 2Q26, underscoring ongoing execution and liquidity risk.